Back to search
Primary Immunodeficiencies (PID)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Primary Immunodeficiencies (PID) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Primary Immunodeficiencies (PID) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary…
Background: \- Researchers are interested in studying disorders that make individuals more susceptible to fungal infections, specifically infections with the C…
Individuals with suspected primary immunodeficiency will be studied and the results compared with healthy controls. Primary immunodeficiency may manifest as rec…
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants follo…
This is a phase III, non-randomized clinical trial (VIP Study) designed to assess the safety and efficacy of V-IMMUNE®, a 5% human normal immunoglobulin prepara…
All patients will receive the investigational medicinal product BP-SCIG 20%, solution for subcutaneous administration, manufactured by BIOPHARMA PLASMA LLC. A l…
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, an…